Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro.

Abdel-Motal UM, Sarkis PT, Han T, Pudney J, Anderson DJ, Zhu Q, Marasco WA.

PLoS One. 2011;6(10):e26473. doi: 10.1371/journal.pone.0026473. Epub 2011 Oct 21.

2.

Prolonged expression of an anti-HIV-1 gp120 minibody to the female rhesus macaque lower genital tract by AAV gene transfer.

Abdel-Motal UM, Harbison C, Han T, Pudney J, Anderson DJ, Zhu Q, Westmoreland S, Marasco WA.

Gene Ther. 2014 Sep;21(9):802-10. doi: 10.1038/gt.2014.56. Epub 2014 Jun 26.

3.

Inhibition of HIV-1 infectivity and epithelial cell transfer by human monoclonal IgG and IgA antibodies carrying the b12 V region.

Mantis NJ, Palaia J, Hessell AJ, Mehta S, Zhu Z, Corth├ęsy B, Neutra MR, Burton DR, Janoff EN.

J Immunol. 2007 Sep 1;179(5):3144-52.

4.

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.

Burton DR, Hessell AJ, Keele BF, Klasse PJ, Ketas TA, Moldt B, Dunlop DC, Poignard P, Doyle LA, Cavacini L, Veazey RS, Moore JP.

Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11181-6. doi: 10.1073/pnas.1103012108. Epub 2011 Jun 20.

5.

Infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp120.

Furuta Y, Eriksson K, Svennerholm B, Fredman P, Horal P, Jeansson S, Vahlne A, Holmgren J, Czerkinsky C.

Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12559-63.

7.

Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention.

Brady JM, Baltimore D, Balazs AB.

Immunol Rev. 2017 Jan;275(1):324-333. doi: 10.1111/imr.12478. Review.

8.

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR.

PLoS Pathog. 2009 May;5(5):e1000433. doi: 10.1371/journal.ppat.1000433. Epub 2009 May 15.

9.

A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement.

Jia L, Xu Y, Zhang C, Wang Y, Chong H, Qiu S, Wang L, Zhong Y, Liu W, Sun Y, Qiao F, Tomlinson S, Song H, Zhou Y, He Y.

Virol J. 2010 Jun 29;7:142. doi: 10.1186/1743-422X-7-142.

10.

Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120.

Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, Ketas T, Marx PA, Klasse PJ, Burton DR, Moore JP.

Nat Med. 2003 Mar;9(3):343-6. Epub 2003 Feb 10.

PMID:
12579198
11.
12.

Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection.

Sagar M, Akiyama H, Etemad B, Ramirez N, Freitas I, Gummuluru S.

J Infect Dis. 2012 Apr 15;205(8):1248-57. doi: 10.1093/infdis/jis183. Epub 2012 Mar 6.

13.

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR.

J Virol. 2001 Sep;75(17):8340-7.

14.

Effect of anti-V3 antibodies on cell-free and cell-to-cell human immunodeficiency virus transmission.

Pantaleo G, Demarest JF, Vaccarezza M, Graziosi C, Bansal GP, Koenig S, Fauci AS.

Eur J Immunol. 1995 Jan;25(1):226-31.

PMID:
7843235
15.

DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.

Gupta S, Clark ES, Termini JM, Boucher J, Kanagavelu S, LeBranche CC, Abraham S, Montefiori DC, Khan WN, Stone GW.

J Virol. 2015 Apr;89(8):4158-69. doi: 10.1128/JVI.02904-14. Epub 2015 Jan 28.

16.

Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.

Miyake A, Akagi T, Enose Y, Ueno M, Kawamura M, Horiuchi R, Hiraishi K, Adachi M, Serizawa T, Narayan O, Akashi M, Baba M, Hayami M.

J Med Virol. 2004 Jul;73(3):368-77.

PMID:
15170630
17.

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.

Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL, Bradney A, Montefiori D, Weinhold KJ.

AIDS. 1998 Dec 24;12(18):2407-15.

PMID:
9875578
18.

Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.

Subbramanian RA, Xu J, Toma E, Morisset R, Cohen EA, Menezes J, Ahmad A.

J Clin Microbiol. 2002 Jun;40(6):2141-6.

Supplemental Content

Support Center